EGFR Exon 20 insertion: Prognostic and predictive values in advanced non-small cell lung cancer, a real-world study.
C Chouaid, T Filleron, D Debieuvre, M Perol, N Girard… - 2021
9062 Background: In Europe, 10-15% of non-squamous non-small cell lung cancer
(nsqNSCLC) have EGFR mutations of which 5-12% are an Exon 20 insertion (20ins).
Methods: Analysis of Epidemio-Strategy and Medical Economics (ESME) Advanced …
Amivantamab compared with real-world therapies in patients with NSCLC with EGFR Exon 20 insertion mutations who have progressed after platinum doublet …
AR Minchom, N Girard, L Bazhenova, SHI Ou… - 2021
9052 Background: Amivantamab is an epidermal growth factor receptor (EGFR)-MET
bispecific antibody with immune cell-directing activity. Amivantamab has
demonstrated efficacy and safety in patients (pts) with EGFR exon 20 insertion …
Real-world response and outcomes in NSCLC patients with EGFR exon 20 insertion mutations.
SHI Ou, HM Lin, JL Hong, Y Yin, S Jin, J Lin, M Mehta… - 2021
9098 Background: There is currently no targeted therapy approved for patients with
EGFR exon 20 insertion mutations (exon20ins) in NSCLC. Real world treatment
outcome evidence for this rare population is limited. This study describes treatment …
Safety and activity of CLN-081 (TAS6417) in NSCLC with EGFR Exon 20 insertion mutations (Ins20).
Z Piotrowska, HA Yu, JCH Yang, M Koczywas, EF Smit… - 2021
9077 Background: NSCLC with EGFR ins20 represents a significant area of unmet
need, with no approved targeted therapies. While several agents targeting EGFR
ins20 are in development, wild-type (WT) EGFR-related adverse events (AEs) have …
Mobocertinib (TAK-788) in EGFR exon 20 insertion (ex20ins)+ metastatic NSCLC (mNSCLC): Additional results from platinum-pretreated patients (pts) and EXCLAIM …
SS Ramalingam, C Zhou, TM Kim, SW Kim, JCH Yang… - 2021
9014 Background: No approved targeted therapies are available for EGFR ex20ins+
mNSCLC. Mobocertinib, a first-in-class, potent, oral TKI targeting EGFR ex20ins
mutations, has Breakthrough Therapy Designation in the US and China for post …
Primary and secondary resistance mechanisms in first, second and third generation tyrosine kinase inhibitors in EGFR mutant non-small cell lung cancer patients.
M Suryavanshi, S Mattoo, SK Sharma, A Mehta… - 2021
… There were 2 cases of complex EGFR exon 19 mutation p.
Glu746_Leu747delinsValPro, 4 cases of EGFR exon 20 insertion, 1 case
of dual EGFR L833V & H835L mutation, 2 cases with EGFR amplification …
Safety and preliminary efficacy from the phase 1 portion of MasterKey-01: A First-in-human dose-escalation study to determine the recommended phase 2 dose …
AM Schram, J Rodon Ahnert, MR Patel, S Jauhari… - 2021
… Cancer types: 12 NSCLC, 5 breast, 4 ovary, 3 biliary, and 12 other. Genomic alterations:
23 HER2 amplification and the following mutations: 11 allosteric HER2, 5 EGFR exon
20 insertion, 5 HER2 exon 20 insertion, 3 EGFR exon 19 del./L858R, and 2 HER3 …
CHRYSALIS-2: A phase 1/1b study of lazertinib as monotherapy and in combination with amivantamab in patients with EGFR-mutant NSCLC.
CA Shu, K Goto, BC Cho, F Griesinger, JCH Yang… - 2021
… Expansion Cohort A is enrolling patients who have progressed on 1st or
2nd-line osimertinib followed by platinum chemotherapy; Expansion Cohort
B is enrolling patients with EGFR exon 20 insertion (Exon20ins) mutation …
Clinical relevance of comprehensive genomic profiling for advanced cancers in India.
S Elizabeth Joseph, A Mathew, SJ Rajappa, N Rohatgi… - 2021
… Among them, 29% was for HER2 amplification (non-breast cancer), 26% for PIK3CA
mutation, 11% for HER2 or EGFR exon 20 insertion mutation (lung cancer), 5% each
for BRAF mutation (non-melanoma), EGFR mutation (non-lung cancer) and MET mutation …